CN115160339B - 醛糖还原酶抑制剂及其使用方法 - Google Patents

醛糖还原酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN115160339B
CN115160339B CN202210711329.3A CN202210711329A CN115160339B CN 115160339 B CN115160339 B CN 115160339B CN 202210711329 A CN202210711329 A CN 202210711329A CN 115160339 B CN115160339 B CN 115160339B
Authority
CN
China
Prior art keywords
alkyl
compound
halogen
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210711329.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115160339A (zh
Inventor
A·沃斯穆特
D·W·兰德里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Priority to CN202210711329.3A priority Critical patent/CN115160339B/zh
Publication of CN115160339A publication Critical patent/CN115160339A/zh
Application granted granted Critical
Publication of CN115160339B publication Critical patent/CN115160339B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cosmetics (AREA)
CN202210711329.3A 2016-06-21 2017-06-21 醛糖还原酶抑制剂及其使用方法 Active CN115160339B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210711329.3A CN115160339B (zh) 2016-06-21 2017-06-21 醛糖还原酶抑制剂及其使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662352784P 2016-06-21 2016-06-21
US62/352,784 2016-06-21
CN201780038647.5A CN109310674B (zh) 2016-06-21 2017-06-21 醛糖还原酶抑制剂及其使用方法
PCT/US2017/038505 WO2017223179A1 (en) 2016-06-21 2017-06-21 Aldose reductase inhibitors and methods of use thereof
CN202210711329.3A CN115160339B (zh) 2016-06-21 2017-06-21 醛糖还原酶抑制剂及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780038647.5A Division CN109310674B (zh) 2016-06-21 2017-06-21 醛糖还原酶抑制剂及其使用方法

Publications (2)

Publication Number Publication Date
CN115160339A CN115160339A (zh) 2022-10-11
CN115160339B true CN115160339B (zh) 2024-05-14

Family

ID=60783884

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210711329.3A Active CN115160339B (zh) 2016-06-21 2017-06-21 醛糖还原酶抑制剂及其使用方法
CN201780038647.5A Active CN109310674B (zh) 2016-06-21 2017-06-21 醛糖还原酶抑制剂及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780038647.5A Active CN109310674B (zh) 2016-06-21 2017-06-21 醛糖还原酶抑制剂及其使用方法

Country Status (22)

Country Link
US (6) US10150779B2 (enExample)
EP (3) EP3757107B1 (enExample)
JP (4) JP6895464B2 (enExample)
CN (2) CN115160339B (enExample)
AU (3) AU2017281082B2 (enExample)
CA (1) CA3025081A1 (enExample)
DK (2) DK3757107T3 (enExample)
ES (2) ES2836500T3 (enExample)
FI (1) FI3757107T3 (enExample)
HR (2) HRP20231563T1 (enExample)
HU (2) HUE064911T2 (enExample)
IL (3) IL304979A (enExample)
LT (2) LT3352754T (enExample)
MX (2) MX391561B (enExample)
NZ (1) NZ748506A (enExample)
PL (1) PL3757107T3 (enExample)
PT (2) PT3757107T (enExample)
RS (1) RS61239B1 (enExample)
SG (2) SG10202012188VA (enExample)
SI (2) SI3352754T1 (enExample)
WO (1) WO2017223179A1 (enExample)
ZA (1) ZA201808506B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
SI3352754T1 (sl) * 2016-06-21 2021-03-31 The Trustees Of Columbia University In The City Of New York Zaviralci aldozne reduktaze in postopki njihove uporabe
IL272246B1 (en) * 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
WO2020167937A1 (en) * 2019-02-12 2020-08-20 Applied Therapeutics, Inc. Methods for treating cutaneous aging
KR20220003529A (ko) * 2019-04-01 2022-01-10 어플라이드 테라퓨틱스 인크. 알도스 리덕타제의 억제제
CN113966396A (zh) 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测
WO2021071965A1 (en) * 2019-10-08 2021-04-15 Applied Therapeutics Inc. Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
WO2021202523A1 (en) 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
MX2022013658A (es) 2020-05-01 2023-03-01 Applied Therapeutics Inc Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa.
US20240033263A1 (en) * 2021-03-18 2024-02-01 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2025219948A1 (en) 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678315A (zh) * 2002-06-14 2005-10-05 武田药品工业株式会社 用于治疗如消化性溃疡的质子泵抑制剂咪唑衍生物的前药
CN103052637A (zh) * 2010-07-16 2013-04-17 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其用途
CN105121414A (zh) * 2013-01-16 2015-12-02 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂和其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) * 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
CA1299178C (en) 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
ES2032749T3 (es) 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
WO1989006651A1 (en) * 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
BR9610207A (pt) 1995-08-28 1999-02-02 American Home Prod Acidos fenóxi acéticos como inibidores da aldose redutase e agentes anti-hiperglicêmicos
US6169087B1 (en) 1997-09-23 2001-01-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
CA2383983C (en) 1998-03-31 2009-09-29 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
YU71403A (sh) 2001-03-30 2006-05-25 Pfizer Products Inc. Piridazinoni kao inhibitori aldoza reduktaze
JP2005527492A (ja) 2002-01-23 2005-09-15 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニスト
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
US20090305963A1 (en) 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
SI3352754T1 (sl) 2016-06-21 2021-03-31 The Trustees Of Columbia University In The City Of New York Zaviralci aldozne reduktaze in postopki njihove uporabe
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678315A (zh) * 2002-06-14 2005-10-05 武田药品工业株式会社 用于治疗如消化性溃疡的质子泵抑制剂咪唑衍生物的前药
CN103052637A (zh) * 2010-07-16 2013-04-17 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其用途
CN105732640A (zh) * 2010-07-16 2016-07-06 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其用途
CN105121414A (zh) * 2013-01-16 2015-12-02 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂和其用途

Also Published As

Publication number Publication date
CN115160339A (zh) 2022-10-11
IL263631B (en) 2021-07-29
JP2021130719A (ja) 2021-09-09
IL304979A (en) 2023-10-01
EP3757107B1 (en) 2023-10-25
PL3757107T3 (pl) 2024-03-18
ZA201808506B (en) 2020-05-27
JP7368419B2 (ja) 2023-10-24
NZ748506A (en) 2025-07-25
SG11201810642XA (en) 2019-01-30
JP2023171614A (ja) 2023-12-01
RU2019101194A3 (enExample) 2020-08-31
CA3025081A1 (en) 2017-12-28
ES2836500T3 (es) 2021-06-25
SI3352754T1 (sl) 2021-03-31
JP2019518779A (ja) 2019-07-04
JP7688681B2 (ja) 2025-06-04
MX2018016122A (es) 2019-08-01
US20250163073A1 (en) 2025-05-22
AU2023204218B2 (en) 2025-09-11
DK3352754T3 (da) 2020-12-07
SG10202012188VA (en) 2021-01-28
US20180237451A1 (en) 2018-08-23
FI3757107T3 (fi) 2023-12-12
RS61239B1 (sr) 2021-01-29
JP6895464B2 (ja) 2021-06-30
EP3352754A1 (en) 2018-08-01
EP3352754A4 (en) 2019-04-17
HUE064911T2 (hu) 2024-04-28
US20200283451A1 (en) 2020-09-10
US12077547B2 (en) 2024-09-03
EP3352754B1 (en) 2020-09-02
IL283809B2 (en) 2024-01-01
HK1259379A1 (en) 2019-11-29
HRP20201905T1 (hr) 2021-01-22
HUE052101T2 (hu) 2021-04-28
HRP20231563T1 (hr) 2024-03-15
US20190300543A1 (en) 2019-10-03
CN109310674B (zh) 2022-07-08
PT3352754T (pt) 2020-12-07
BR112018076244A2 (pt) 2019-03-26
JP2025124733A (ja) 2025-08-26
US10870658B2 (en) 2020-12-22
AU2017281082A1 (en) 2018-12-06
EP3757107A1 (en) 2020-12-30
AU2021203801A1 (en) 2021-07-15
IL263631A (en) 2019-01-31
WO2017223179A1 (en) 2017-12-28
RU2019101194A (ru) 2020-07-23
US10647726B2 (en) 2020-05-12
PT3757107T (pt) 2023-12-14
IL283809B1 (en) 2023-09-01
US20210284652A1 (en) 2021-09-16
ES2966094T3 (es) 2024-04-18
CN109310674A (zh) 2019-02-05
EP4316603A2 (en) 2024-02-07
US11498925B2 (en) 2022-11-15
DK3757107T3 (da) 2023-11-27
MX391561B (es) 2025-03-21
US20230312599A1 (en) 2023-10-05
LT3757107T (lt) 2023-12-11
LT3352754T (lt) 2021-02-25
MX2021014938A (es) 2022-01-24
SI3757107T1 (sl) 2024-02-29
AU2021203801B2 (en) 2023-04-06
AU2017281082B2 (en) 2021-03-18
AU2023204218A1 (en) 2023-07-27
EP4316603A3 (en) 2024-04-17
IL283809A (en) 2021-07-29
US10150779B2 (en) 2018-12-11

Similar Documents

Publication Publication Date Title
CN115160339B (zh) 醛糖还原酶抑制剂及其使用方法
CN105732640B (zh) 醛糖还原酶抑制剂及其用途
RU2795195C2 (ru) Ингибиторы альдозоредуктазы и способы их применения
HK40105726A (en) 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
HK40044237A (en) 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
HK40044237B (en) 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
HK1259379B (en) Aldose reductase inhibitors and methods of use thereof
BR112018076244B1 (pt) Compostos inibidores da aldose reductase, composição farmacêutica e uso dos mesmos
HK1223925B (zh) 醛糖还原酶抑制剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant